Tag - PSNL

Developments

Personalis presents positive NeXT Personal assay data in early-stage lung cancer

Personalis (NASDAQ:PSNL) presented positive data on its NeXT Personal platform’s ability to detect and monitor residual and recurrent disease (MRD) in patients with early-stage lung cancer. NeXT Personal is a whole...

October 23, 2023

Markets

HCW starts Personalis at buy; PT $30

H.C Wainwright launched coverage of Personalis (NASDAQ:PSNL) with a “buy” rating and $30 price target. The stock closed at $21.88 on Aug. 26. Personalis is a developer of next generation sequencing technologies and...

August 27, 2020

Tag - PSNL

Personalis presents positive NeXT Personal assay data in early-stage lung cancer

HCW starts Personalis at buy; PT $30

General

More